Peroxisome proliferator-activated receptor gamma (PPARγ), a member of the nuclear receptor family of ligand-activated transcription factors that regulates gene expression via the formation of protein heterodimers with the retinoic X receptor (RXR), is a key nuclear receptor regulating adipocyte differentiation and glucose homeostasis. 10 Peroxisome proliferator-activated receptor gamma has been reported to interact with multiple signalling pathways, including BCL2, NFκB, p53, p21, STAT, cyclooxygenase-2 (COX-2) and Cyclin D1. 11 Additionally, PPARγ is highly expressed in certain cancer cell. However, its function in tumour progression remains controversial. 10, 12 Some previous studies have suggested that the activation of PPARγ can prevent tumours in tissues such as the lung, colon, prostate, breast and others, 13, 14 while others have revealed that activated PPARγ is oncogenic. 18, 19 Therefore, the role of PPARγ in tumorigenesis needs to be further clarified. In this study, we aimed to identify the effects of PPARγ in BCa.
Ligands of PPARγ contain endogenetic fatty acids and thiazolidinedione (TZD) classes of anti-diabetic drugs such as pioglitazone, which has weak PPARα activity, and rosiglitazone, which is highly selective for PPARγ. 22 Some clinical trials have shown that PPARγ agonists are associated with increased risks of bone fractures 23, 24 heart failure 25 and BCa. 26 For instance, an increased incidence of BCa has been observed, as a side effect in rodent toxicity studies using PPAR agonists to examine anti-diabetic effects, 18 whereas other studies indicated no increased risk. 27, 28 Recently, a comprehensive retrospective study showed an increased hazard ratio with long-term, high-dose treatment with pioglitazone in BCa. 29 In addition, some compounds that antagonize PPARγ have been reported to inhibit the proliferation or invasiveness of human tumour cell lines, such as colon carcinoma, renal cell carcinoma, oesophageal carcinoma, hepatocellular carcinoma and others 20, 21, 30 Therefore, in our study, we chose GW9662, the selective and irreversible PPARγ antagonist, 31 to treat the BCa cells and detected the alterations in viability and motility.
Our group has focused on novel biomarkers and pathways for the long-term prevention of BCa progression. Our previous studies have suggested that HJURP may regulate apoptosis and proliferation in BCa cells through the PPARγ-SIRT1 feedback loop 32 and that simvastatin can induce cell cycle arrest in G1/G0 phase and inhibit proliferation in BCa cells via the PPARγ signalling pathway. 33 In this study, we aimed to investigate the function of PPARγ gene and its effects on BCa tumorigenesis.
| MATERIAL S AND ME THODS

| Ethical statement for human bladder tissues
As described by Wang et al 33 
| BCa cell lines
| Reverse transcription and quantitative realtime PCR
The cDNA was synthesized from 1 μg of total RNA using the RevertAid Ace quantitative real-time PCR (qPCR RT) kit (Toyobo, Shanghai, China).
For qRT-PCR analysis, 1 μg of cDNA was used in each reaction in a final volume of 20 μL with iQ™ SYBR ® -Green Supermix (Bio-Rad, Shanghai, China 
| Cell culture experiments
| Knockdown of PPARγ in BCa cells
Negative control small interfering RNA (siRNA) and PPARγ target siRNA were synthesized by Genepharma (Shanghai, China).
The sense sequence of PPARγ target siRNA (si-PPARγ) was as 
| PPARγ antagonist treatment
Bladder cancer cells were first incubated for 24 hours and subse- 
| Clonogenic survival assay
To six-well plates were added 800 UM-UC-3 cells/well, 1000 T24 cells/well and 3000 5637 cells/well for growth into colonies for 7-10 days. After removing the medium, fixing the cells with 4% PFA, and staining with crystal violet for 30 minutes, imaging and counting were performed.
| Methyl thiazolyl tetrazolium assay
Into 96-well plates were pipetted 3000 BCa cells in 200 μL medium for growth for 48 hours. To each well was added in 20 μL methyl thiazolyl tetrazolium (MTT) and incubated for 4 hours at 37°C, discarding the medium and dissolving the formazan precipitate in 150 μL DMSO. The absorbance at 490 nm was then detected using a microplate reader (Cat. no. SpectraMax M2; Molecular Devices, Berkeley, CA, USA).
| Transwell chamber invasion and migration assay
To 
| Protein Analyses
| Isolation of total protein and Western blot analysis
Bladder cancer cells were lysed and sonicated on ice in radioimmunoprecipitation assay buffer including phosphatase inhibitor and protease inhibitor (Sigma-Aldrich) for approximately 30 minutes. They were then centrifuged at 12 000 g for 15 minutes, and the supernatant was collected. The Bradford protein assay (Bio-Rad, Munich, Germany) was used to determine the protein concentration using bovine serum albumin (BSA) as the standard. Protein was separated using 7.5%-10% SDS-PAGE gels and transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA), which was then blocked in 5% fat-free milk (BD biosciences) at room temperature for 2 hours and incubated with primary antibodies overnight ( Table 2) and secondary antibodies for 2 hours (Table 3 ). Bands were detected using an enhanced chemiluminescence (ECL) kit (Bio-Rad, Hercules, CA, USA) and visualized with Biomax MR films (Kodak, Rochester, NY).
| Immunofluorescence staining
Bladder cancer cells were seeded on the coverslips, washed with cold Tables 2 and 3 ).
| Haematoxylin and eosin staining
All the tissue paraffin sections from xenotransplanted cancer samples were stained with haematoxylin and eosin (H&E). They were then serially deparaffinized and rehydrated in xylene, 100% ethanol, 96% ethanol, 80% ethanol, 70% ethanol and H 2 O. The sections were subsequently stained with 10% haematoxylin (Sigma-Aldrich) for 7 minutes, and 1% eosin (Sigma-Aldrich) with 0.2% glacial acetic acid was used to stain the cytoplasm after washing to reveal the nuclei. The tissue sections were washed and dehydrated successively in 70%, 80%, 96% and 100% ethanol, followed by 10 minutes in xylene. Images of the sections were obtained using an inverted phase contrast microscope (Cat. #DMI 1; Leica, Wetzlar, Germany).
| Xenograft mouse model
Male BALB/c nude mice aged 3 weeks were obtained from Beijing HFK Bioscience Co., Ltd. in Beijing, China. After a 1-week adaptation period, the mice that were maintained in a temperature and humidity-controlled and specific pathogen-free environment in the laboratory animal facility of Zhongnan Hospital of Wuhan University, were injected into the right flank with 3 × 10 6 T24 cells dispersed in 0.2 mL PBS. Ten days later, mice with transplanted tumours that were approximately 3 × 3 mm were randomly assigned to one of two groups (n = 5). GW9662 (1 mg/kg body weight) and vehicle were injected intraperitoneally every other day for 2 weeks. Tumour size was measured every 2 days using a caliper, and the values were 
| Statistical analyses
All experiments were performed at least three times, and representative data were from three iterations. One-way ANOVA and two-tailed Student's T test were used to evaluate the statistical significance of differences between subgroups. All the statistical analyses were conducted with spss 16.0, and the cut-off level was set at probability values of P < 0.05. cis.hku.hk/miRNACancerMAP/index.php). 36 The Cancer Genome
| RE SULTS
| Up-regulation of PPARγ in BCa tissues compared with normal and paracancerous tissues
Atlas Bladder urothelial carcinoma datasets were chosen and the cut-off P-value was set at 0.01. Gene ontology (GO) enrichment analysis revealed that PPARγ was involved in regulation of cell proliferation, positive regulation of biosynthetic process, regulation of cell death and so on ( Figure 1D ; Table S1 ). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis indicated that
PPARγ was related to cell cycle, focal adhesion, apoptosis, PI3K-AKT signalling pathway and so on ( Figure 1E ; Table S2 ).
| Knockdown of PPARγ impaired the viability of BCa cells
To detect the effects of PPARγ on biological behaviours in BCa,
we chose four distinct PPARγ target siRNAs to transfect BCa Figure 2D ; Figure S1D ). The clonogenic survival results showed a distinct reduction in colony-forming efficiency ( Figure 2E ; Figure   S1C ), which was statistically significant ( Figure 2F ). Moreover, Ki-67, an important marker of cell proliferation, was significantly reduced in the siRNA-treated group compared with the NC group ( Figure 2C ).
| Down-regulation of PPARγ inhibited cell motility with alterations in AKT/GSK3β/EMTrelated proteins
Metastasis was the greatest challenge in clinical management of tumours, which was associated with cell motility. Our transwell invasion and migration assay revealed that knockdown of PPARγ could decrease the cell invasion and migration rate of BCa cells ( Figure 3A ; Figure S1E ), which was confirmed by the statistical analysis ( Figure 3B ). In addition, proteins related to EMT were analysed by Western blot and IF staining, which showed that E-cadherin, a marker of the epithelium, was up-regulated, and the mesenchymal markers N-cadherin and vimentin exhibited an especially strongly down-regulation in the PPARγ-siRNA group (Figure 3C,D; Figure S1H ). Moreover, consistent with our KEGG TA B L E 3 List of secondary antibodies and counterstaining of nuclei pathway enrichment, the proteins associated with the AKT/ GSK3β signalling pathway were altered, for example, p-GSK3β was up-regulated and p-AKT was down-regulated ( Figure 3C ). 
| Knockdown of PPARγ induced cell cycle arrest in G0/G1 phase but had no significant effect on apoptosis
Pathway enrichment analysis revealed that PPARγ was related to cell cycle, apoptosis and PI3K-AKT signalling pathway ( Figure 1E ).
Therefore, we used flow cytometry to assess the effect of PPARγ Figure 4C ; Figure S1I ). We also noted that the upstream indicators of the cell cycle pathway, such as p21 and p27, were up-regulated, and phosphorylated/total AKT was down-regulated ( Figure 4C ; Figure S1I ). However, as shown by the flow cytometry analysis, PPARγ deficiency could not induce significant apoptosis in BCa cells (Figure 4A ,B; Figure S1G ).
| The PPARγ antagonist GW9662 inhibited the motility and proliferation of BCa cells
To further study the effect of drug inhibitor of PPARγ protein on Figure 5E ).
| GW9662 suppressed BCa cell growth in vivo
We established a mouse model by transplanting T24 cells Figure 6B ). The cancer tissues dissected from mice were stained with H&E ( Figure 6C ). Moreover, the IF results indicated that the positive staining for Ki-67, which is an important marker of cell proliferation, 37 was considerably lower in the GW9662-injected group in comparison to the vehicle group ( Figure 6D ).
| D ISCUSS I ON
Our group has revealed a variety of potential biomarkers 32, 38, 39 based on transcriptome data of normal bladder tissues vs BCa , and the results were in accordance with the IF staining of Ki-67. E, The influence of PPARγ downregulation on cell survival was measured by the clonogenic survival assay and (F) statistical analysis of three independent results. *P < 0.05, **P < 0.01, ***P < 0.001 tissues. 34, 41 Most of them are related to the PPAR signalling pathway, which could represent a connection between fatty acid/lipid metabolism and BCa. 33 The PPARs, including the PPARα, PPARβ/δ and PPARγ subtypes encoded by different genes, are a family group of nuclear receptors. 42 Recent studies have also shown significantly activation of the PPARγ signalling pathway in BCa, with a highly enriched PPARγ mRNA expression. 43, 44 Consistently, in this study, we found an up-regulated PPARγ expression in BCa both at mRNA and protein levels ( Figure 1B,C) . To investigate the effect of PPARγ on BCa, we generated a cell model with PPARγ deficiency using siRNA transfection. Indeed, we validated the knockdown efficiency of PPARγ at the gene expression and protein levels in the BCa T24 cell line (Figure 2A -C, Figure S1A ,B).
Moreover, our results revealed that the down-regulation of PPARγ could inhibit the proliferation of T24 cells, which might be caused by cell cycle arrest in G0/G1 phase. Furthermore, proteins related to cell cycle regulation, CDK2/4/6 and CCND1, were all decreased after si-PPARγ treatment. Cyclin-dependent kinases (CDKs) are a family of protein kinases that play crucial roles in cell cycle regulation. 46 Among them, CDK6 and CDK4 are responsible for releasing out from G0 phase to enter G1 phase, 47, 48 while CDK2
protein plays a role in G1 phase. 49 which has been demonstrated to play a crucial role in cancer cell invasion and migration. 52 The association of vimentin and cytokeratin was also revealed in the transitional cell carcinoma genesis of urinary bladder patients, and thus could be a favourable marker in the early diagnosis of transitional BCa. 53 Consistently, in this study, the potential BCa marker vimentin was reduced in BCa T24 cells treated with PPARγ deficiency. The phosphorylation of AKT at Ser9 could inhibit the activity of GSK-3β. 54 Consistently, in our study, we noted that phosphorylated/total AKT was down-regulated and phosphorylated/total GSK3β was up-regulated, which indicated that the alteration of EMT might be regulated via the AKT/GSK3β signalling pathway.
To better understand the effect of PPARγ on BCa, GW9662 was used for subsequent pharmacologic inhibition, a potent and pure antagonist of PPARγ. 31 Recent studies have revealed that GW9662, with or without PPARγ ligands, could be a potential therapeutic strategy targeting glioblastoma stem cells. 55, 56 In accordance with the knockdown assays, our results revealed that GW9662 could inhibit the proliferation of BCa 5637, T24 and UM-UC-3 cells in a time and dose-dependent manner. The invasion and migration rate were also reduced in BCa cells treated with GW9662, with reversed EMT markers, which could suggest tumour malignancy. 57, 58 However, we did not notice the same changes of AKT/GSK3β-related proteins F I G U R E 4 Down-regulation of PPARγ induced cell cycle arrest in G0/G1 phase. A, Flow cytometry analysis of cell cycle and apoptosis in T24 cells with siRNA treatment. B, Statistical analysis of the cell cycle showed a significantly increased percentage of cell populations in G0/ G1 phase. However, there was no obvious effect on apoptosis after the knockdown of PPARγ. C, Proteins related to G0/G1 phase in T24 cells were analysed by Western blotting. The upstream indicator p21/p27 was up-regulated and phosphorylated/total AKT was down-regulated. All values are presented as the mean ± SD from at least three independent research results. *P < 0.05, **P < 0.01, ns means no significance as in PPARγ knockdown assay. The reason might be that GW9662 treatment could cause multiple alterations of pathway-related proteins, which could be caused by the drug effect that was different from PPARγ knockdown. And the deep mechanism still needs to be further studied. Interestingly, we found that GW9662 did not mod- BCa and GW9662 has the potential to become a targeted therapeutic strategy against BCa.
F I G U R E 5 GW9662 inhibited the viability and motility of BCa cells. A, To determine the appropriate concentrations of GW9662, the proliferation of UM-UC-3 and T24 cells treated with GW9662 at different concentrations (0, 0.1, 1, 10, 20 and 40 μmol/L) were detected using the methyl thiazolyl tetrazolium assay. The results after treatment for 48 h are shown. B, Alterations of cell survival were detected using the clonogenic forming assay after treatment with GW9662. The colony number in each well was counted and statistically analysed. Cell types and drug concentrations are indicated. C, The migration assay showed a decreased number of migrated T24 and UM-UC-3 cells after treatment with GW9662, as confirmed by the statistical analysis. D, GW9662 treatment with different concentrations inhibited the invasion rate of BCa UM-UC-3 and T24 cells. The scale bar is indicated. E, Western blot analysis of vimentin, slug, MMP2 and MMP9 showed a considerable decrease after GW9662 treatment. GAPDH was used as internal reference. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001
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